Результаты поиска

Обновленная информация о соответствующей последовательности для спасательной терапии в Мультимиломе.

Нынешние стратегии лечения привели к непредсказуемым улучшениям в управлении миеломой (ММ) с течением времени. Вместе с тем в последние годы все более серьезной проблемой становится сопротивление лечению, особенно в том, что касается рефракции линалидомида и, в последнее время, рефрагментации даратумумаба и линалидомида, даже в условиях первой линии. Это сопротивление осложняет идентификацию алгоритма оптимального лечения для пациентов с рецидивом/отходом MM, особенно при первом рецидиве. В ходе этого обзора мы сосредоточим внимание на нынешних стратегиях в отношении пациентов, страдающих от С

Совпадение в полном тексте источника
… 10.3 months and OS 29.8 months) with a low-level of toxicity in a phase 2 trial. 39 , 40 However, this study did not include patients with anti-CD38 mAb treatment, and an Italian real-life experience has reported a significantly lower response to this combination in Dara-refractory patients. 41 , 42 Melphalan … approved chemotherapy drug in the treatment of MM, according to data from the Ocean trial, namely in patients with relapsed/refractory multiple myeloma who have not received an ASCT or progressed >36 months after receiving an ASCT. 43 , 44 It is a hybrid molecule that combines the alkylating agent melphalan …

A head-to-head comparison of the EQ-5D-5L and 15D descriptive systems and index values in a general population sample.

BackgroundThe EQ-5D-5L and 15D are generic preference-accompanied health status measures with similar dimensions. In this study, we aim to compare the measurement properties of the EQ-5D-5L and 15D descriptive systems and index values in a general population sample.MethodsIn August 2021, an online cross-sectional survey was conducted in a representative adult general population sample (n = 1887). The EQ-5D-5L and 15D descriptive systems and index values were compared in terms of ceiling and floor, informativity (Shannon's Evenness index), agreement, convergent and known-groups validity for 41

Совпадение в полном тексте источника
… Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma. Eur J Haematol. 2001;66(5):328–36. doi: 10.1034/j.1600-0609.2001.066005328.x. 24. …

Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: A systematic review and meta-analysis.

IntroductionThe global pandemic of coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It seems that there is an association between blood cancer and an increased risk of severe COVID-19. This study aimed to review the literature reporting the COVID-19 outcomes in patients with hematological malignancies.Material and methodsIn this systematic review and meta-analysis, Pubmed, Embase, and Web of Science databases were searched using the following keywords: COVID-19, SARS-CoV-2, blood cancer, myeloma, lymphoma, and leukemia. All the

Совпадение в полном тексте источника
… hyperuricemia | AIHA | Discharge Zamani 48 | Iran | Jan 2021 | Case report | 1 | 35 | F | AML | Chemotherapy | less than 1 y | RT‐PCR, CT scans | NR | Dyspnea, malaise, cough | NR | AMN | Death Krengli 24 | Italy | Dec 2020 | Case report | 1 | 62 | F | MM | Bortezomib‐thalidomide‐DEX, cyclophosphamide, melphalan … trioxide | 1/297 (0.34%) | 4 BEACOPP | 1/297 (0.34%) | 4 Brentuximab | 1/297 (0.34%) | 4 Cytosine arabinose | 1/297 (0.34%) | 4 DA‐EPOCH | 1/297 (0.34%) | 4 Doxorubicin | 1/297 (0.34%) | 4 Hydrochloride | 1/297 (0.34%) | 4 Fludarabine | 1/297 (0.34%) | 4 ICE | 1/297 (0.34%) | 4 IFRT | 1/297 (0.34%) | 4 Melphalan …

Extracellular Vesicles in Multiple Myeloma-Cracking the Code to a Better Understanding of the Disease.

Multiple myeloma (MM) is a plasma cell-derived malignancy that stands for around 1.5% of newly discovered cancer cases. Despite constantly improving treatment methods, the disease is incurable with over 13,000 deaths in the US and over 30,000 in Europe. Recent studies suggest that extracellular vesicles (EVs) might play a significant role in the pathogenesis and evolution of MM. Further investigation of their role could prove to be beneficial in establishing new therapies and hence, improve the prognosis of MM patients. What is more, EVs might serve as novel markers in diagnosing and monitorin

Совпадение в полном тексте источника
… Interestingly, the chemotherapeutics that are used for MM treatment (such as bortezomib, carfilzomib, and melphalan) may increase the osteoclastogenic function of MM-EVs. … Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): A randomised, open-label, phase 3 trial Lancet 2020 395 132 141 10.1016/S0140-6736(19)32956-3 31836199 111. Ashour R. Ri M. Aly S.S. Yoshida T. Tachita T. Kanamori T. Aoki S. …

Characterizing the Patient Journey in Multiple Myeloma: Qualitative Review.

BACKGROUND: The patient experience of multiple myeloma (MM) is multifaceted and varies substantially between individuals. Current published information on the patient perspective and treatment of MM is limited, making it difficult to gain insights into patient needs regarding the condition. OBJECTIVE: In this review, a combined research method approach (ie, the review of published literature and social media posts) was undertaken to provide insight into patients' perspectives on the burden and treatment of MM, the impact of the COVID-19 pandemic, and the impact of MM on caregivers of patients

Совпадение в полном тексте источника
… Patients also reported gastrointestinal side effects associated with undergoing chemotherapy (including bendamustine, cisplatin, cyclophosphamide, doxorubicin, etoposide, and melphalan). … In an exploratory investigation into concepts that influenced treatment choices for patients with MM and that analyzed patients (N=30) receiving proteasome inhibitors (66.7%), immunomodulatory drugs (56.7%), chemotherapy (30%; bendamustine, cisplatin, cyclophosphamide, doxorubicin, etoposide, and melphalan …

Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis.

BackgroundCurrently, three chimeric antigen receptor (CAR)-T cell products axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel have been approved by the U.S. Food and Drug Administration for the treatment of large B cell lymphoma, which provide a novel and promising choice for patients with relapsed or refractory to traditional anti-tumor treatments. Thus, it is pertinent to describe the efficacy and safety profile of the three products available by summarizing the current evidence.MethodsTwo reviewers independently searched the Embase, PubMed, Web of Science, and Cochrane

Совпадение в полном тексте источника
… Other Tumor Types A study involving 10 patients with MM revealed that patients receiving tisa-cel following autologous stem cell transplantation and high-dose melphalan experienced clinical benefit; eight patients among them achieved a partial response or better without occurrence of severe CRS and … Anti-CD19 CAR T Cells With High-Dose Melphalan and Autologous Stem Cell Transplantation for Refractory Multiple Myeloma . JCI Insight ( 2019 ) 4 : 1 – 14 . doi: 10.1172/jci.insight.127684 PMC6478404 30830874 33 Maude SL Laetsch TW Buechner J Rives S Boyer M Bittencourt H . …

Management of Patients With Hematologic Malignancies During the COVID-19 Pandemic: Practical Considerations and Lessons to Be Learned.

The COVID-19 pandemic has created unprecedented hurdles to the delivery of care to patients with cancer. Patients with hematologic malignancies appear to have a greater risk of SARS-CoV-2 infection and severe disease due to myelosuppression and lymphopenia. The first challenge, therefore, is how to continue to deliver effective, curative therapy to vulnerable patients and at the same time avoid exposing them, and their health care teams (HCT), to SARS-CoV-2. An additional challenge is the timely completion of the diagnostic and staging studies required to formulate appropriate treatment plans.

Совпадение в полном тексте источника
… Newly Diagnosed Patients Eligible for ASCT High dose melphalan followed by ASCT is the treatment of choice for younger patients with newly diagnosed MM who are eligible for such a procedure ( 33 ). … Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study …

Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.

Weekly ixazomib with lenalidomide-dexamethasone (Rd) is feasible and has shown activity in newly diagnosed multiple myeloma (NDMM) patients. This phase 1/2 study (NCT01383928) evaluated the recommended phase 2 dose (RP2D), pharmacokinetics, safety and efficacy of twice-weekly ixazomib plus Rd in NDMM; 64 patients were enrolled across both phases. Patients received twice-weekly oral ixazomib 3·0 or 3·7 mg plus lenalidomide 25 mg and dexamethasone 20 mg (10 mg in cycles 9-16) for up to sixteen 21-day cycles, followed by maintenance with twice-weekly ixazomib alone. No dose-limiting toxicities we

Совпадение в полном тексте источника
… . & Boccadoro, M. (2010) Bortezomib‐melphalan‐prednisone‐thalidomide followed by maintenance with bortezomib‐thalidomide compared with bortezomib‐melphalan‐prednisone for initial treatment of multiple myeloma: a randomized controlled trial. Journal of Clinical Oncology, 28, 5101–5109. …

Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action.

Hepatocellular carcinoma (HCC) is a dreaded malignancy that every year causes half a million deaths worldwide. Being an aggressive cancer, its incidence exceeds 700,000 new cases per year worldwide with a median survival of 6-8 months. Despite advances in prognosis and early detection, effective HCC chemoprevention or treatment strategies are still lacking, therefore its dismal survival rate remains largely unchanged. This review will characterize currently available chemotherapeutic drugs used in the treatment of HCC. The respective mode(s) of action, side effects and recommendations will be

Совпадение в полном тексте источника
… Morabito F Bringhen S Larocca A Bortezomib, Melphalan, Prednisone [VMP] versus Melphalan, Prednisone, Thalidomide [MPT] in elderly newly diagnosed Multiple Myeloma patients: a retrospective case matched study . Am J Hematol 2013 ; 89 : 355 - 62 . 24273190 10.1002/ajh.23641 42. …

Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.

Hematologic malignancies are one of the most common cancers, and the incidence has been rising in recent decades. The clinical and molecular features of hematologic malignancies are highly heterogenous, and some hematologic malignancies are incurable, challenging the treatment, and prognosis of the patients. However, hematopoiesis and oncogenesis of hematologic malignancies are profoundly affected by epigenetic regulation. Studies have found that methylation-related mutations, abnormal methylation profiles of DNA, and abnormal histone deacetylase expression are recurrent in leukemia and lympho

Functional Recovery Following Intensive Upfront Therapy in Multiple Myeloma Patients With Poor Performance Status: A Case Series.

Patients with newly diagnosed multiple myeloma (MM) may present with profound functional impairment due to high disease burden, and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 4 is often viewed as a barrier to intensive therapy despite potential reversibility. We report six newly diagnosed, bedbound MM patients (ECOG 4) treated with individualized multi-agent regimens incorporating proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies when feasible. Advanced features included extensive skeletal disease, renal dysfunction, hyperviscosity

Совпадение в полном тексте источника
… Classic reports documented that even on older chemotherapy, such as melphalan/prednisone, some patients with myeloma-induced paraplegia due to spinal cord compression could regain ambulation. 14 Our series builds on this concept with contemporary therapies: for example, Patient 1 and Patient 5, who were …

Наркотики и вакцины: систематический обзор литературы.

Калановые лимфомы Т-клеток (КХЛ) представляют собой тип неходгкинской лимфомы, которая обычно связана с кожей. Она имеет различные подтипы, включая микоз-фангоиды (MF), синдром Сезари (SS), первичную анапластическую большую лимфому (PC-ALCL), лимфоматоидный папулос (LyP) и подкожную панникулитную лимфому, аналогичную Т-клеток (SPTCL). Имеется несколько сообщений о случаях, рецидивах или прогрессе в работе ЦТИКС путем использования конкретных лекарственных средств. Мы стремимся определить характерные особенности ТХМЛ, связанные с наркотиками и вакцинами. Систематический поиск проводился с испол

Совпадение в полном тексте источника
… There were two cases each of melphalan, peginterferon, and pembrolizumab. Additionally, estradiol patch, goserelin, carbamazepine, phenytoin, glatiramer, hydrochlorothiazide, atenolol, benralizumab, nivolumab, tocilizumab, rituximab, and secukinumab were also reported. …

The prevalence of anemia in people with chronic kidney disease after hematopoietic stem cell transplantation.

The hematopoietic stem cell transplantation (HSCT) is performed for various hematological diseases. Chronic kidney disease (CKD) occurs relatively often after HSCT. Anemia after HSCT may be due to CKD and/or other reasons. The aim of this study is to assess the prevalence of anemia and its possible relationship to the presence of CKD in patients at least 3 months after HSCT. The study included 156 patients who underwent allogeneic HSCT treatment in our center in the years 1998 to 2021 due to different hematologic pathologies (acute myeloid leukemia, acute lymphoblastic leukemia, lymphoma, and

Совпадение в полном тексте источника
… They were mainly based on cyclophosphamide, etoposide, others were based on busulphan and cyclophosphamide, fludarabine and busulphan, busulphan and melphalan, etc. The prevalence of CKD in our population was 22. Prevalence of CKD after HSCT was reported in some studies [ 13–21 ]. …

Clinical efficacy of Thalidomide combined with PAD Regimen in patients with multiple Myeloma.

ObjectiveTo evaluate the clinical efficacy of thalidomide combined with PAD regimen in patients with multiple myeloma (MM).MethodsIt was a Clinical comparative study. A total of 120 patients with MM were admitted at Beijing Aerospace General Hospital from September 2020 to June 2022 randomly divided into two groups, with 60 patients in each group. The study group was treated with thalidomide combined with a PAD regimen (bortezomib, doxorubicin and dexamethasone), while the control group with a PAD regimen alone. After treatment, the therapeutic effect, adverse drug reactions, bone metabolic ma

Совпадение в полном тексте источника
… Their compatibility with novel drugs improves the clinical response rate. 16 Another study 17 has found that bortezomib has a synergistic effect with dexamethasone, and can reverse the resistance of MM to melphalan, doxorubicin, etc. …

Real-world utilization and healthcare costs for multiple myeloma: A retrospective analysis of patients in Singapore.

Multiple myeloma, a hematological malignancy, imposes a significant financial burden on healthcare systems. Health technology assessments (HTA) and economic evaluations play vital roles in reimbursement decisions and cost containment. This study aimed to explore healthcare utilization patterns and costs among myeloma patients in Singapore through a retrospective analysis of 605 patients treated at two cancer centers. Data encompassing demographics, treatment utilization, and billing were extracted from electronic records, and a cost analysis was performed from the perspective of the Singapore

Совпадение в полном тексте источника
… These guidelines predominantly advocate for proteasome inhibitor‐based therapies, as they offer superior response rates and improved survival outcomes, alongside the use of thalidomide, melphalan, lenalidomide, and cyclophosphamide [ 14 ]. …

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Subcutaneous daratumumab (DARA SC) plus standard-of-care (SoC) regimens in multiple myeloma (MM) across lines of therapy in the phase 2 PLEIADES study: initial results of the DARA SC plus carfilzomib/dexamethasone (D-Kd) cohort, and updated results for the DARA SC plus bortezomib/melphalan/prednisone …

Cross-cultural translation and adaptation of Functional Assessment of Cancer Therapy - Multiple Myeloma tool - MM1 and LEU3 - for Portuguese.

OBJECTIVE: To describe of the translation from English to Portuguese and adaption process of subitems of the Functional Assessment of Cancer Therapy - Multiple Myeloma. METHODS: In the first phase, translations from English into Portuguese of two subitems of Functional Assessment of Cancer Therapy - Multiple Myeloma were performed. Subsequently, a consensus and back translation were conducted, and, finally, translation and back translations were reviewed by four independent bilingual experts. In the second phase, the translated subitems were applied, along with a questionnaire, to 10 native P

Совпадение в полном тексте источника
… This was because the use of alkylating agents was affected due to the impairment of the mobilization of hematopoietic cells in the pre-transplant phase, and at that time, melphalan was a major chemotherapeutic agent. …

Value of influenza vaccines in cancer patients during the coronavirus (COVID-19) pandemic: a cross-sectional study.

BackgroundAccording to the recommendation of the Centers for Disease Control and Prevention (CDC), getting influenza vaccines during the coronavirus (COVID-19) pandemics is especially important for people with certain underlying medical conditions, like cancer. Due to the similarities between the symptoms of influenza and COVID-19, receiving the flu vaccine in suspicious cases can be helpful because it will make it easier to request a medical test and diagnosis. In this study, the value of influenza vaccination in the cancer population was investigated.MethodsIn a cross-sectional study, all ca

Совпадение в полном тексте источника
… Table 1 The chemotherapy program for cancer patients eligible to receive the flu vaccine during the COVID-19 pandemic Melph melphalan; PRD prednison; Gem gemcitabine; Cis cisplatin; Capaci capecitabine; Nav Navelbine; TEC taxotere-epirubicin-cyclophosphamide; PVC procarbazine-lomustine-vincristine; Carb …

Case series: MRD negativity assessment using 11C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma.

Complete response (CR) is an important favorable factor for survival in multiple myeloma (MM). However, CR patients continue to relapse, especially in the presence of minimal residual disease (MRD). Bone marrow (BM) MRD is predictive of progression-free survival (PFS) in MM. However, myeloma outside the BM aspiration site may result in subsequent relapse despite MRD-negativity. Therefore, positron emission tomography-computed tomography (PET-CT) based on F-fluorodeoxyglucose (FDG) is a complementary tool to monitor residual disease in MM. However, FDG may miss myeloma lesions that are not FDG-

Совпадение в полном тексте источника
… Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma . N Engl J Med 2018 ; 378 : 518 – 528 . 29231133 10.1056/NEJMoa1714678 …

How to calculate the dose of chemotherapy.

Body surface area-dosing does not account for the complex processes of cytotoxic drug elimination. This leads to an unpredictable variation in effect. Overdosing is easily recognised but it is possible that unrecognised underdosing is more common and may occur in 30% or more of patients receiving standard regimen. Those patients who are inadvertently underdosed are at risk of a significantly reduced anticancer effect. Using published data, it can be calculated that there is an almost 20% relative reduction in survival for women receiving adjuvant chemotherapy for breast cancer as a result of u

Совпадение в полном тексте источника
… 383 391 10.1038/86882 11279519 MathijssenRHJVerweijJMajaJAde JongeMJANooterKStoterGSparreboomA 2002 Impact of body-size measures on irinotecan clearance: Alternative dosing recommendations J Clin Oncol 20 81 87 11773157 10.1200/JCO.2002.20.1.81 McIntyreORLeoneLPajakTF 1978 The use of intravenous melphalan …